Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms

Kristen L. Partyka, Melissa L. Randolph, Karen A. Lawrence, Harvey Cramer, Howard Wu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Ancillary molecular testing has been recommended for thyroid fine-needle aspirates (FNA) with indeterminate cytologic diagnoses. Rosetta Genomics and Interpace Diagnostics have developed assays that can utilize direct smears as the testing substrate. Methods: A retrospective study of indeterminate thyroid FNAs with known histologic follow-up was performed. One Diff-Quik-stained smear and one Papanicolaou-stained smear with similar cellularity (at least 60-100 lesional cells) from each case were sent to Rosetta and Interpace, respectively, for analysis. The results were directly compared and correlated with the final histopathology. Neither company was aware of the follow-up histologic findings in these cases. Results: A total of 10 thyroid FNAs were identified from our 2015 files. The cytologic diagnoses included follicular lesion of undetermined significance (FLUS, n=5), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN, n=4), and suspicious for malignancy (SM, n=1). Of the seven cases with benign histology, six smears were classified as benign by the RosettaGX microRNA classifier, and one case was designated as suspicious. Five cases were negative by both ThyGenX oncogene panel and ThyraMIR microRNA classifier. One case was negative by ThyGenX and positive on follow-up ThyraMIR, and one case was positive for KRAS mutation and positive on ThyraMIR. Both the RosettaGX and ThyGenX/ThyraMIR tests demonstrated positive results for the three histologically malignant cases. Conclusion: This study demonstrates that two molecular testing platforms performed equally well using our stained direct smears. Both molecular tests revealed a 100% negative predictive rate. RosettaGX showed a 75% positive predictive value in comparison to 60% for ThyGenX/ThyraMIR.

Original languageEnglish (US)
JournalDiagnostic Cytopathology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Needles
Thyroid Gland
MicroRNAs
Papanicolaou Test
Neoplasms
Genomics
Oncogenes
Histology
Retrospective Studies
Mutation
Diff Quik
SM 1

Keywords

  • Direct smears
  • FNA
  • Molecular testing
  • The Bethesda System
  • Thyroid cytology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing : A comparison of two proprietary testing platforms. / Partyka, Kristen L.; Randolph, Melissa L.; Lawrence, Karen A.; Cramer, Harvey; Wu, Howard.

In: Diagnostic Cytopathology, 01.01.2017.

Research output: Contribution to journalArticle

@article{838a4fd1abcf4cb4bc9d9f059f8150cd,
title = "Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms",
abstract = "Background: Ancillary molecular testing has been recommended for thyroid fine-needle aspirates (FNA) with indeterminate cytologic diagnoses. Rosetta Genomics and Interpace Diagnostics have developed assays that can utilize direct smears as the testing substrate. Methods: A retrospective study of indeterminate thyroid FNAs with known histologic follow-up was performed. One Diff-Quik-stained smear and one Papanicolaou-stained smear with similar cellularity (at least 60-100 lesional cells) from each case were sent to Rosetta and Interpace, respectively, for analysis. The results were directly compared and correlated with the final histopathology. Neither company was aware of the follow-up histologic findings in these cases. Results: A total of 10 thyroid FNAs were identified from our 2015 files. The cytologic diagnoses included follicular lesion of undetermined significance (FLUS, n=5), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN, n=4), and suspicious for malignancy (SM, n=1). Of the seven cases with benign histology, six smears were classified as benign by the RosettaGX microRNA classifier, and one case was designated as suspicious. Five cases were negative by both ThyGenX oncogene panel and ThyraMIR microRNA classifier. One case was negative by ThyGenX and positive on follow-up ThyraMIR, and one case was positive for KRAS mutation and positive on ThyraMIR. Both the RosettaGX and ThyGenX/ThyraMIR tests demonstrated positive results for the three histologically malignant cases. Conclusion: This study demonstrates that two molecular testing platforms performed equally well using our stained direct smears. Both molecular tests revealed a 100{\%} negative predictive rate. RosettaGX showed a 75{\%} positive predictive value in comparison to 60{\%} for ThyGenX/ThyraMIR.",
keywords = "Direct smears, FNA, Molecular testing, The Bethesda System, Thyroid cytology",
author = "Partyka, {Kristen L.} and Randolph, {Melissa L.} and Lawrence, {Karen A.} and Harvey Cramer and Howard Wu",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/dc.23902",
language = "English (US)",
journal = "Diagnostic Cytopathology",
issn = "8755-1039",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing

T2 - A comparison of two proprietary testing platforms

AU - Partyka, Kristen L.

AU - Randolph, Melissa L.

AU - Lawrence, Karen A.

AU - Cramer, Harvey

AU - Wu, Howard

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Ancillary molecular testing has been recommended for thyroid fine-needle aspirates (FNA) with indeterminate cytologic diagnoses. Rosetta Genomics and Interpace Diagnostics have developed assays that can utilize direct smears as the testing substrate. Methods: A retrospective study of indeterminate thyroid FNAs with known histologic follow-up was performed. One Diff-Quik-stained smear and one Papanicolaou-stained smear with similar cellularity (at least 60-100 lesional cells) from each case were sent to Rosetta and Interpace, respectively, for analysis. The results were directly compared and correlated with the final histopathology. Neither company was aware of the follow-up histologic findings in these cases. Results: A total of 10 thyroid FNAs were identified from our 2015 files. The cytologic diagnoses included follicular lesion of undetermined significance (FLUS, n=5), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN, n=4), and suspicious for malignancy (SM, n=1). Of the seven cases with benign histology, six smears were classified as benign by the RosettaGX microRNA classifier, and one case was designated as suspicious. Five cases were negative by both ThyGenX oncogene panel and ThyraMIR microRNA classifier. One case was negative by ThyGenX and positive on follow-up ThyraMIR, and one case was positive for KRAS mutation and positive on ThyraMIR. Both the RosettaGX and ThyGenX/ThyraMIR tests demonstrated positive results for the three histologically malignant cases. Conclusion: This study demonstrates that two molecular testing platforms performed equally well using our stained direct smears. Both molecular tests revealed a 100% negative predictive rate. RosettaGX showed a 75% positive predictive value in comparison to 60% for ThyGenX/ThyraMIR.

AB - Background: Ancillary molecular testing has been recommended for thyroid fine-needle aspirates (FNA) with indeterminate cytologic diagnoses. Rosetta Genomics and Interpace Diagnostics have developed assays that can utilize direct smears as the testing substrate. Methods: A retrospective study of indeterminate thyroid FNAs with known histologic follow-up was performed. One Diff-Quik-stained smear and one Papanicolaou-stained smear with similar cellularity (at least 60-100 lesional cells) from each case were sent to Rosetta and Interpace, respectively, for analysis. The results were directly compared and correlated with the final histopathology. Neither company was aware of the follow-up histologic findings in these cases. Results: A total of 10 thyroid FNAs were identified from our 2015 files. The cytologic diagnoses included follicular lesion of undetermined significance (FLUS, n=5), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN, n=4), and suspicious for malignancy (SM, n=1). Of the seven cases with benign histology, six smears were classified as benign by the RosettaGX microRNA classifier, and one case was designated as suspicious. Five cases were negative by both ThyGenX oncogene panel and ThyraMIR microRNA classifier. One case was negative by ThyGenX and positive on follow-up ThyraMIR, and one case was positive for KRAS mutation and positive on ThyraMIR. Both the RosettaGX and ThyGenX/ThyraMIR tests demonstrated positive results for the three histologically malignant cases. Conclusion: This study demonstrates that two molecular testing platforms performed equally well using our stained direct smears. Both molecular tests revealed a 100% negative predictive rate. RosettaGX showed a 75% positive predictive value in comparison to 60% for ThyGenX/ThyraMIR.

KW - Direct smears

KW - FNA

KW - Molecular testing

KW - The Bethesda System

KW - Thyroid cytology

UR - http://www.scopus.com/inward/record.url?scp=85042018972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042018972&partnerID=8YFLogxK

U2 - 10.1002/dc.23902

DO - 10.1002/dc.23902

M3 - Article

C2 - 29446257

AN - SCOPUS:85042018972

JO - Diagnostic Cytopathology

JF - Diagnostic Cytopathology

SN - 8755-1039

ER -